MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals Current Ratio 2011-2026 | ALNY
Annual Current Ratio Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.19 | 1.02 | 0.946 | 0.957 | 1.19 | 1.43 | 4.87 | 6.69 | 12.2 | 5.1 | 17.8 | 7.83 | 4.72 | 2.6 | 1.88 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.8 | 0.946 | 4.7 |
Quarterly Current Ratio Alnylam Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.06 | 1.03 | 1.02 | 1.01 | 1 | 0.95 | 0.95 | 0.96 | 0.89 | 0.93 | 0.96 | 0.98 | - | 1.13 | 1.19 | 1.28 | 1.32 | 1.4 | 1.43 | 1.43 | 1.43 | 1.43 | 2.5 | 2.5 | 2.5 | 2.5 | 5.77 | 5.77 | 5.77 | 5.77 | 8.74 | 8.74 | 8.74 | 8.74 | 3.69 | 3.69 | 3.69 | 3.69 | 11.4 | 11.4 | 11.4 | 11.4 | 7.53 | 7.53 | 7.53 | 7.53 | 2.8 | 2.8 | 2.8 | 2.8 | 1.87 | 1.87 | 1.87 | 1.87 | 1.72 | 1.72 | 1.72 | 1.72 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.4 | 0.89 | 3.65 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M |  Germany |
 |
Amgen
AMGN
|
1.44 | $ 350.54 | 0.79 % | $ 189 B |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.94 | $ 19.39 | -0.56 % | $ 906 M | USA |
 |
Altimmune
ALT
|
5.09 | $ 3.45 | 3.14 % | $ 304 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
2.2 | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
I-Mab
IMAB
|
8.96 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B |  France |
 |
Aytu BioScience
AYTU
|
1.47 | $ 2.62 | 0.21 % | $ 16.5 M | USA |
 |
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
0.889 | $ 219.22 | -1.2 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
2.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | USA |
 |
Benitec Biopharma
BNTC
|
43.4 | $ 11.01 | 0.27 % | $ 453 M | USA |
 |
ARCA biopharma
ABIO
|
28.7 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
1.6 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.81 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
1.61 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
2.39 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.98 | - | 10.36 % | $ 9.8 M | USA |
 |
Compugen Ltd.
CGEN
|
7.46 | $ 2.12 | 1.44 % | $ 198 M |  Israel |
 |
Acasti Pharma
ACST
|
13.4 | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
1.31 | $ 1.58 | 3.95 % | $ 185 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
3.27 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
0.41 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | USA |
 |
Cellectis S.A.
CLLS
|
1.31 | $ 3.39 | 1.5 % | $ 116 M | France |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
3.57 | $ 0.6 | -1.79 % | $ 6.87 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
11.3 | $ 12.85 | 0.86 % | $ 774 M | USA |
 |
Atreca
BCEL
|
2.02 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
2.37 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.14 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
4.13 | - | -10.95 % | $ 876 K | USA |
 |
CorMedix
CRMD
|
1.96 | $ 6.43 | 2.88 % | $ 463 K | USA |
 |
Cara Therapeutics
CARA
|
1.83 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.05 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
1.47 | - | -74.18 % | $ 955 K | USA |
 |
CytomX Therapeutics
CTMX
|
2.88 | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
0.372 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
0.629 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
2.47 | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
9.51 | $ 21.1 | 4.59 % | $ 3.47 B | USA |
 |
Dyadic International
DYAI
|
3.51 | $ 0.9 | -4.79 % | $ 25.9 M | USA |
 |
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
3.76 | $ 4.29 | 1.06 % | $ 712 M | Canada |